UBS Group Analysts Give Bayer (FRA:BAYN) a €110.00 Price Target

UBS Group set a €110.00 ($127.91) target price on Bayer (FRA:BAYN) in a research note issued to investors on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the topic of a number of other reports. Baader Bank set a €123.00 ($143.02) target price on shares of Bayer and gave the company a buy rating in a research report on Tuesday. JPMorgan Chase & Co. set a €70.00 ($81.40) target price on shares of Bayer and gave the company a neutral rating in a research report on Tuesday. HSBC set a €63.00 ($73.26) target price on shares of Bayer and gave the company a neutral rating in a research report on Monday, July 1st. Deutsche Bank set a €70.00 ($81.40) target price on shares of Bayer and gave the company a neutral rating in a research report on Friday, July 19th. Finally, Berenberg Bank set a €67.00 ($77.91) target price on shares of Bayer and gave the company a neutral rating in a research report on Tuesday, June 11th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of €80.61 ($93.73).

FRA BAYN opened at €58.92 ($68.51) on Tuesday. The firm has a fifty day moving average of €58.28. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: Equity Income

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.